Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
BURLINGTON, Mass., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the expansion of its drug development team with three strategic hires
View HTML
Toggle Summary Aldeyra Therapeutics Reports Second Quarter 2014 Financial Results
BURLINGTON, Mass. , Aug. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced its financial results for the second quarter ended June
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
BURLINGTON, Mass., July 23, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced that it will issue its financial results for the second
View HTML
Toggle Summary Aldeyra Therapeutics to Join Russell Microcap Index
BURLINGTON, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, announced today that it will be added to the Russell Microcap Index when Russell
View HTML
Toggle Summary Aldeyra Therapeutics Appoints Stephen Tulipano Chief Financial Officer
BURLINGTON, Mass. , June 19, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Stephen Tulipano has joined Aldeyra as its Chief Financial
View HTML
Toggle Summary Aldeyra Therapeutics Reports First Quarter 2014 Financial Results
BURLINGTON, Mass. , June 11, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the first quarter ended March 31, 2014 .
View HTML
Toggle Summary Aldeyra Therapeutics' Data on Lead Candidate NS2 to be Presented at Society for Investigative Dermatology 2014 Annual Meeting
Results Suggest Novel Approach to Treating Dry Skin and Dry Eye Diseases
View HTML
Toggle Summary Aldeyra Therapeutics Announces Closing of Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced initial public offering of
View HTML
Toggle Summary Aldeyra Therapeutics Prices Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics ("Aldeyra"), a biotechnology company focused on the development of products to treat diseases where free aldehydes are thought to be important to the pathology, today announced the pricing of its initial public offering of
View HTML